Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

The biggest buzz around GLP-1 drugs these days has nothing to do with weight loss. And that might lead to some problems for ...

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...

As the popularity of the type-2 diabetes drugs have risen, researcher have been looking into different aspects of it to ...

Mounjaro kick-started my weight loss, but true success came from hard work, persistence and changing bad habits ...